Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study

被引：0
|
作者：
McGlashan, TH
Zipursky, RB
Perkins, DO
Addington, J
Woods, SW
Miller, TJ
Lindborg, SR
Trzaskoma, Q
Hawkins, K
Breier, A
机构：
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ N Carolina, Chapel Hill, NC 27515 USA
[4] Yale Univ, New Haven, CT 06520 USA
[5] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
BIOLOGICAL PSYCHIATRY | 2004年 / 55卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
807
引用
收藏
页码：226S / 226S
页数：1
相关论文
共 50 条
  • [31] Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study
    Therese F. Nielsen
    Pernille Ravn
    Yu Z. Bagger
    Lise Warming
    Claus Christiansen
    Osteoporosis International, 2004, 15 : 168 - 174
  • [32] Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study
    Nielsen, TF
    Ravn, P
    Bagger, YZ
    Warming, L
    Christiansen, C
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (02) : 168 - 174
  • [33] Risedronate is safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study
    Boonen, S.
    Delmas, P. D.
    Wenderoth, D.
    Stoner, K. J.
    Eusebio, R.
    Orwoll, E. S.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S119 - S119
  • [34] Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Kryzhanovskaya, Ludmila
    Schulz, S. Charles
    McDougle, Christopher
    Frazier, Jean
    Dittmann, Ralf
    Robertson-Plouch, Carol
    Bauer, Theresa
    Xu, Wen
    Wang, Wei
    Carlson, Janice
    Tohen, Mauricio
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (01): : 60 - 70
  • [35] Characterization and treatment of the schizophrenia prodrome: Results of a three-year prospective study
    Cornblatt, B
    Lencz, T
    Obuchowski, M
    Pappadopulos, E
    Shah, M
    Becker, JA
    Coscia, D
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 3 - 3
  • [36] OPTIMIZING TREATMENT WITH LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Loebel, Antony
    Silva, Robert
    Goldman, Robert
    Watabbe, Kei
    Pikalov, Andrei
    Cucchiaro, Josephine
    Kane, John M.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S321
  • [37] Autologous Myoblasts for the Treatment of Fecal Incontinence Results of a Phase 2 Randomized Placebo-controlled Study (MIAS)
    Boyer, Olivier
    Bridoux, Valerie
    Giverne, Camille
    Bisson, Aurelie
    Koning, Edith
    Leroi, Anne-Marie
    Chambon, Pascal
    Dehayes, Justine
    Le Corre, Stephanie
    Jacquot, Serge
    Bastit, Dominique
    Martinet, Jeremie
    Houivet, Estelle
    Tuech, Jean-Jacques
    Benichou, Jacques
    Michot, Francis
    ANNALS OF SURGERY, 2018, 267 (03) : 443 - 450
  • [38] Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia
    Wassef, AA
    Dott, SG
    Harris, A
    Brown, A
    O'Boyle, M
    Meyer, WJ
    Rose, RM
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) : 357 - 361
  • [39] Consumer satisfaction in schizophrenia - A 2-year randomized controlled study of two community-based treatment programs
    Malm, U
    Lewander, T
    NORDIC JOURNAL OF PSYCHIATRY, 2001, 55 : 91 - 96
  • [40] Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs
    Malm, U
    Ivarsson, B
    Allebeck, P
    Falloon, IRH
    ACTA PSYCHIATRICA SCANDINAVICA, 2003, 107 (06) : 415 - 423
12345